Live federal data · NADAC weekly · Part D CY24

Brimonidine Auvi-Q

Brimonidine vs Auvi-Q — $267.0M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated 14 Jul 2026

NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

alpha-Adrenergic Agonist

Brimonidine

Brand: ALPHAGAN P

First FDA approval: 2001-07-10

alpha-Adrenergic Agonist

Auvi-Q

First FDA approval: 2012-11-15

Lowest NADACAcquisition cost floor across all NDCs

$0.494Per unit

$309.38Per unit

Average NADACAcross all dosage forms and strengths

$11.82Up to $39.80

$309.59Up to $309.85

Generic manufacturersActive ANDA holders — FDA Orange Book

1116 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$267.0MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

4.1M1.3M beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$65Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

3Minimal friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes11 manufacturers

NoBrand-only